JPMorgan analyst Anupam Rama lowered the firm’s price target on Sarepta to $213 from $217 and keeps an Overweight rating on the shares. The analyst updated the company’s model post the approval of Elevidys in 4-5 year-old Duchenne muscular dystrophy patients.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRPT: